Overview

Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis

Status:
Completed

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

This is an open label study designed to examine the effects on concurrent administration of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone in subjects with symptomatic castrate resistant prostate cancer and with bone metastases, in both the pre- and post- chemotherapy setting. Both medications are approved by the US Food and Drug Administration for this indication.

Phase:

Phase 2

Details

Lead Sponsor:

Carolina Research Professionals, LLC

Collaborator:

Bayer

Treatments:

Abiraterone Acetate
Hormones
Prednisone
Radium Ra 223 dichloride
Succinylcholine